<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-theophylline.xml</id>
  <title>Recalls Watch: Theophylline</title>
  <link rel="self" href="https://recalls.watch/feed/substance-theophylline.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-11-04T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/100038/</id>
    <title>Brandywine Pharmaceuticals, LLC: Theophylline Extended-Release Tablets and 1 more</title>
    <link href="https://recalls.watch/recall/fda/100038/"/>
    <updated>2026-11-04T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97406/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Theophylline extended-release tablets 400mg</title>
    <link href="https://recalls.watch/recall/fda/97406/"/>
    <updated>2025-08-20T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96867/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Theophylline</title>
    <link href="https://recalls.watch/recall/fda/96867/"/>
    <updated>2025-06-04T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: OOS results reported for the Dissolution (by UV) test.</summary>
  </entry>
</feed>
